Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906182 | 0.88 | BDKRB1 (0.43) | BDKRB1KMT2AMAPK1NLRP3MTNR1A | |
| SCHEMBL8066192 | 0.88 | BDKRB1 (0.45) | BDKRB1KMT2AMAPK1MTNR1AMTNR1B | |
| SCHEMBL15906183 | 0.87 | KMT2A (0.44) | BDKRB1KMT2AMAPK1NLRP3CNR2 | |
| SCHEMBL10440490 | 0.85 | BDKRB1 (0.41) | BDKRB1KMT2AMAPK1ALDH1A1NPC1 | |
| SCHEMBL13578463 | 0.85 | BDKRB1 (0.41) | BDKRB1KMT2AMAPK1MTNR1AMTNR1B | |
| SCHEMBL15906184 | 0.83 | BDKRB1 (0.44) | BDKRB1KMT2AMAPK1NLRP3MTNR1A | |
| SCHEMBL8058534 | 0.78 | BDKRB1 (0.45) | BDKRB1KMT2AMAPK1MTNR1AMTNR1B | |
| SCHEMBL13578460 | 0.75 | BDKRB1 (0.41) | BDKRB1KMT2AMAPK1MTNR1AMTNR1B | |
| SCHEMBL16158946 | 0.75 | KMT2A (0.48) | BDKRB1KMT2AMAPK1NLRP3L3MBTL1 | |
| SCHEMBL3790292 | 0.74 | KMT2A (0.42) | BDKRB1KMT2AMAPK1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | BDKRB1 170/4885KMT2A 1434/4885MAPK1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.